Genfit S.A. (XUPB.MU)
Chart Events
Performance Outlook
| Previous Close | 2.9600 |
| Open | 2.9600 |
| Bid | 3.2200 x 0 |
| Ask | 3.3200 x 0 |
| Day's Range | 2.9600 - 2.9600 |
| 52 Week Range | 2.9200 - 4.3400 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 152.744M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for XUPB.MU
Related Research
- GlobeNewswire
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
US Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and European Medicine Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor.Acceptance triggers a first milestone payment. Further milestones are expected upon US and European launches which could now happen in 2Q24 in the US (FDA PDUFA1 action date: June 10, 2024) and 2H24 in Europe. These milestones total approximately 89M€. Launches i
- GlobeNewswire
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
New Drug Application granted priority review with PDUFA date set for June 10, 2024European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade Paris (France), December 07, 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Dr
- GlobeNewswire
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
The paper published in Journal of Hepatology demonstrates that NIS2+™ technology could significantly reduce liver biopsy failure rate and maximizes accuracy of patient selection for MASH1 clinical trialsGrowing body of clinical evidence: this is the third paper on NIS2+™ that has been published in a leading medical journal in 2023 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 6, 2023- GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical co
